Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 19/20 | 1.00 |
| ▸ | NSD2 | O96028 | 3/20 | 1.00 |
| ▸ | NSD3 | Q9BZ95 | 3/20 | 1.00 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.98 |
| ▸ | KDM1A | O60341 | 1/20 | 0.98 |
| ▸ | MTOR | P42345 | 1/20 | 0.98 |
| ▸ | RAB9A | P51151 | 1/20 | 0.98 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.92 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20535174 | 1.00 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1NPC1 | |
| Hydrochloric Acid SCHEMBL29849313 | 1.00 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1NPC1 | |
| Hydrochloric Acid SCHEMBL15668608 | 0.99 | EHMT2 (0.98) | EHMT2NSD2NSD3EHMT1NPC1 | |
| SCHEMBL29351415 | 0.99 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1NPC1 | |
| SCHEMBL366593 | 0.99 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1NPC1 | |
| Water SCHEMBL21610936 | 0.98 | EHMT2 (0.98) | EHMT2NSD2NSD3EHMT1NPC1 | |
| SCHEMBL14940754 | 0.96 | EHMT2 (1.00) | EHMT2NSD2NSD3EHMT1NPC1 | |
| SCHEMBL15280407 | 0.94 | EHMT2 (0.94) | EHMT2NSD2NSD3EHMT1NPC1 | |
| SCHEMBL21593815 | 0.93 | EHMT2 (0.88) | EHMT2NSD2NSD3EHMT1NPC1 | |
| SCHEMBL15280410 | 0.92 | EHMT2 (0.98) | EHMT2NSD2NSD3EHMT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992500-B2 | Use of methylation inhibitors for the treatment of autoimmune diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2024-05-28 | — | — | US | claimed |
| US-20210128600-A1 | Use of Methylation Inhibitors for the Treatment of Autoimmune Diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2021-05-06 | — | — | US | claimed |
| EP-4691479-A2 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-11992500-B2 | Use of methylation inhibitors for the treatment of autoimmune diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4194548-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-3472303-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | IDEAYA BIOSCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20210254006-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING LACTAM COMPOUNDS | IDEAYA BIOSCIENCES, INC. | 2021-08-19 | — | — | US | disclosed |
| US-11078277-B2 | Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-08-03 | — | — | US | disclosed |
| US-20210128600-A1 | Use of Methylation Inhibitors for the Treatment of Autoimmune Diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3411063-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | INST NAT SANTE RECH MED (FR) | 2020-11-04 | — | — | EP | disclosed |
| EP-2914298-A2 | INHIBITION OF HISTONE METHYLTRANSFERASE FOR CARDIAC REPROGRAMMING | Duke University (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140301991-A1 | Methods for Generating Cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140235526-A1 | Methods for Generating Cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2750509-A1 | METHODS FOR GENERATING CARDIOMYOCYTES | The J. David Gladstone Institutes (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2014071323-A2 | INHIBITION OF HISTONE METHYLTRANSFERASE FOR CARDIAC REPROGRAMMING | DUKE UNIVERSITY (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20130216503-A1 | Methods for Generating Cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2013033213-A1 | METHODS FOR GENERATING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES (US) | 2013-03-07 | — | — | WO | disclosed |
| EP-2563907-A2 | METHODS FOR GENERATING CARDIOMYOCYTES | The J. David Gladstone Institutes (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011139688-A2 | METHODS FOR GENERATING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | AHR, MCL1, ARNT | EHMT2 289/4885NSD2 806/4885NSD3 714/4885 |
| US-20210254006-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING LACTAM COMPOUNDS | AHR, MCL1, HES1 | EHMT2 575/4885NSD2 425/4885NSD3 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.